Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 105 publications
Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.
Journal: Nanomedicine (London, England)
Published: July 08, 2026
A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.
Journal: Nanomedicine (London, England)
Published: June 02, 2026
Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer.
Journal: International journal of molecular sciences
Published: May 30, 2026
Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.
Journal: Biomedicines
Published: March 03, 2026
Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer.
Journal: Molecular cancer therapeutics
Published: September 24, 2025
Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer.
Journal: Molecular cancer therapeutics
Published: September 24, 2025
Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.
Journal: The Journal of clinical investigation
Published: September 15, 2025
Rapid Discrimination of High-Grade Prostate Cancer Using Label-Free Fluorescence Lifetime Measurements.
Journal: medRxiv : the preprint server for health sciences
Published: July 15, 2025
The Oncometabolite 2-Hydroxyglutarate Is Upregulated in Post-Prostatectomy PSA Recurrence of Prostate Cancer: A Metabolomic Analysis.
Journal: Molecules (Basel, Switzerland)
Published: June 17, 2025
IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer.
Journal: Molecular cancer therapeutics
Published: June 09, 2025
Last Updated: 09/26/2026